Literature DB >> 10448343

Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2.

P J White1, G P Garnett.   

Abstract

BACKGROUND: Genital infection with herpes simplex virus (HSV) is common and can cause severe morbidity, over many years in some cases. Aciclovir provides suppressive therapy but there is debate over the effects of its use on the spread of infection.
OBJECTIVES: To explore the influence of the natural history of genital HSV and the impact of antiviral therapy.
METHODS: A simple mathematical model of HSV-2 transmission dynamics was developed, and parameter values estimated from published data.
RESULTS: The relative durations of the risk of transmitting HSV-2 and the duration of therapy generate a non-linear relation between the duration of antiviral therapy and the reduction in prevalence infection. If there is a wide distribution of risk of HSV-2 transmission over the course of an infection then practicable aciclovir use is unlikely to have any great impact on disease transmission dynamics.
CONCLUSIONS: There are still many uncertainties in the transmission dynamics of HSV-2. In particular, infectiousness over the course of an infection requires more detailed exploration. To have a significant impact on the prevalence of HSV-2 aciclovir use would have to be widespread and for a long duration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448343      PMCID: PMC1758177          DOI: 10.1136/sti.75.1.49

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  29 in total

1.  A general model of sexually transmitted disease epidemiology and its implications for control.

Authors:  R C Brunham; F A Plummer
Journal:  Med Clin North Am       Date:  1990-11       Impact factor: 5.456

2.  A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.

Authors:  S L Spruance; S K Tyring; B DeGregorio; C Miller; K Beutner
Journal:  Arch Intern Med       Date:  1996 Aug 12-26

3.  Oral acyclovir, palliative therapy for genital herpes: will it change the epidemiology?

Authors:  M E Guinan
Journal:  Sex Transm Dis       Date:  1985 Jan-Mar       Impact factor: 2.830

Review 4.  Sexually transmitted diseases and sexual behavior: insights from mathematical models.

Authors:  G P Garnett; R M Anderson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

5.  Acyclovir should not be approved for marketing without prescription.

Authors:  H H Handsfield
Journal:  Sex Transm Dis       Date:  1996 May-Jun       Impact factor: 2.830

6.  Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment.

Authors:  S E Straus; K D Croen; M H Sawyer; A G Freifeld; J M Felser; J K Dale; H A Smith; C Hallahan; S N Lehrman
Journal:  JAMA       Date:  1988-10-21       Impact factor: 56.272

Review 7.  The development and use of the concept of a sexually transmitted disease core.

Authors:  J C Thomas; M J Tucker
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

8.  The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes.

Authors:  J R Williams; D J Nokes; G F Medley; R M Anderson
Journal:  Epidemiol Infect       Date:  1996-02       Impact factor: 2.451

9.  Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes.

Authors:  D M Koelle; J Benedetti; A Langenberg; L Corey
Journal:  Ann Intern Med       Date:  1992-03-15       Impact factor: 25.391

Review 10.  Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy.

Authors:  L Corey; J Benedetti; C Critchlow; G Mertz; J Douglas; K Fife; A Fahnlander; M L Remington; C Winter; J Dragavon
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

View more
  5 in total

Review 1.  Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes.

Authors:  N O'Farrell
Journal:  Sex Transm Infect       Date:  1999-12       Impact factor: 3.519

2.  Comparison of risk factors for four sexually transmitted infections: results from a study of attenders at three genitourinary medicine clinics in England.

Authors:  G Hughes; M Catchpole; P A Rogers; A R Brady; G Kinghorn; D Mercey; N Thin
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

3.  Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models.

Authors:  M Lipsitch; T H Bacon; J J Leary; R Antia; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  The potential epidemiological impact of a genital herpes vaccine for women.

Authors:  G P Garnett; G Dubin; M Slaoui; T Darcis
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

5.  Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo.

Authors:  Wenwen Dai; Yu Wu; Jinpeng Bi; Shuai Wang; Fang Li; Wei Kong; Julien Barbier; Jean-Christophe Cintrat; Feng Gao; Daniel Gillet; Weiheng Su; Chunlai Jiang
Journal:  Viruses       Date:  2018-03-09       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.